posted
IDM Pharma Presents Preliminary Results from Phase II UVIDEM(R) Melanoma Vaccine Clinical Trial Tuesday June 5, 9:00 am ET - Results show UVIDEM was well-tolerated with signs of durable disease control in advanced melanoma patients -
IRVINE, Calif., June 5 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI - News) today presented preliminary results from a Phase II UVIDEM (IDD-3) melanoma vaccine clinical trial (DC-MEL-202). The results showed that UVIDEM was well tolerated with evidence of efficacy and induction of immune response in patients with progressive metastatic melanoma. ADVERTISEMENT
The data were presented by Merrick I. Ross, M.D., Professor of Surgery, Chief, Melanoma Section, Department of Surgical Oncology at The University of Texas M. D. Anderson Cancer Center in Houston as an oral presentation titled "Clinical and immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi- institutional phase II clinical trial" (# 3004) at the 2007 American Society of Clinical Oncology (ASCO) 43rd annual meeting in Chicago.
"We are in great need of new drugs to treat our patients with metastatic melanoma" said Dr. Ross. "The preliminary analysis of the phase II clinical trial with IDM Pharma's cancer vaccine, UVIDEM, suggests that several patients with advanced melanoma attained durable control of their disease after a treatment stimulating their own immune system cells. Additionally, the side effects experienced by our patients were minimal," he added.
Study design and findings
DC-MEL-202 is a single arm, two-stage Phase II trial designed to evaluate clinical and immunological activities and the safety of a multivalent dendritic cell-based vaccine in patients with in-transit or low volume metastatic melanoma. Thirty-three patients were treated in the study and the results to date are as follows:
-- Clinical response (RECIST): out of 30 patients evaluable for efficacy, 9 (30%) showed evidence of clinical benefit (1 complete response (CR), 2 partial responses (PR) and 6 stable disease (SD)) with duration of response ranging from 9.4 to 26.5 months. -- Assessment of pathological response in target sites in 4 patients (2 PR, 2 SD) showed: -- complete pathological regression after resection of target sites in 2 patients; and -- two patients were rendered free of disease after clinical stable disease and surgery of lung metastases. -- Progression free survival (PFS) was 4.8 months with a median follow-up of 12 months. -- Overall survival (OS) has not yet been reached as 21 patients are still alive. The survival rate at 9 months was 70%. -- Immune response: 26 out of 29 evaluated patients (90%) showed detectable TAA-specific CD8+ T cells with 18 patients (62%) showing boosted or appearance of anti-TAA specific CD8+ T cells. -- UVIDEM was well tolerated with toxicity limited to mild events with only one possibly related serious adverse event (SAE) reported (age related macular degeneration).
posted
I love this stock. I only played it twice so far but made a double digit gain both times. I had to work today so I missed it. I would recommend this stock to newbies trying to grow their accounts. Instead of gambling with pinkies, they can just put IDMI on their watch list every day, and once it starts moving get in imediately. Playing this just 3 times in one month would be huge for a newbie! ! !
I only been trading NASDAQ stocks for almost a year and still don't know a whole lot. So I could even be considered a Newbie. But I know what works. I have a few favorite Naz stocks under $20 that I know move well on my watch list. And I just basicaly watch them like a hawk all day, until one of them I know moves well moves on news or just hot air. Sometimes its boring and I waste a whole day cause nothing moves, but I make huge money when they do move, cause Im in at the begging of the move. Still cant read charts well or do DD like an expert, So if it works, it works. My philosophy is...If it isn't broke don't fix it...mabey improve it, Im working on reading charts better.
If Newbies had less the $25k I would recommend they get an account with prodigy trading. They let you daytrade with less than only $2,500 and they give you 4x buying power for Big Board stocks. So if you just wait for a big move like IDMI or DNDN or a stock like that that you are familiar with and how it moves, you can go all in and if it goes up 25%, with 4x buying power you realy just doubled your money. Do that a few times and you are in good shape. Thats basicaly my strategy. Im not a great trader but I just watch a few stock that I know move well every day, and wait for one to move.
GROW is my favorite ! ! !
.....I wish I didn't have to work today cause IDMI, FFHL, and LUNA moved well.
I read almost every post at the Wall Street Pit every day.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
